Evidence-Based Research Hub
Plain-language guides based on peer-reviewed research from Johns Hopkins, Imperial College London, and NYU. No hype — just what the studies actually show.
Topic Research Hubs
Best Psilocybin for Depression
40+ articles
Explore hub →
Best Psilocybin for Anxiety
35+ articles
Explore hub →
Best Psilocybin for PTSD
30+ articles
Explore hub →
Psilocybin vs. Antidepressants
70+ comparisons
Explore hub →
Complete Microdosing Guide
40+ protocols
Explore hub →
Where to Buy Psilocybin
25+ buying guides
Explore hub →
Best Supplements — Ranked & Reviewed
Anxiety disorders affect 40 million Americans. Microdosing psilocybin is showing strong results in clinical and observational research. This complete guide covers protocols, dosing, what to expect, and how to start safely.
The default mode network is overactive in depression, driving rumination and negative self-referential thinking. Psilocybin disrupts it more effectively than any other known intervention. Here's the neuroscience.
Grief is not a disorder — but prolonged grief disorder affects 10% of bereaved people and can be as debilitating as major depression. Here's what the research shows about psilocybin as a targeted intervention.
Millions of people on antidepressants are asking whether they can microdose psilocybin. Here's what the pharmacology and clinical data actually show — including the serotonin syndrome question.
SSRIs take 4–6 weeks to work. Psilocybin microdosing typically shows effects in 1–3 weeks. Here's a head-to-head comparison of onset, efficacy, side effects, and mechanism.
Social anxiety disorder affects 12% of the population and is notoriously difficult to treat. Here's what the clinical evidence shows about psilocybin as a targeted intervention.
PTSD nightmares affect 70–90% of PTSD patients and are one of the most treatment-resistant symptoms. Here's what the clinical evidence shows about psilocybin as a targeted intervention.
The most common question from people starting a microdosing protocol for depression: how long until it works? Here's what the research and clinical data actually show.
Treatment-resistant depression affects 30% of people with MDD. Standard antidepressants have failed them. Here's what the clinical evidence shows about psilocybin as a last resort — and why it's becoming a first choice.
Morning anxiety — the cortisol spike that makes the first hour of the day the worst — affects millions. Here's what the research shows about microdosing psilocybin as a targeted intervention.
Veterans have a PTSD rate 15x higher than civilians. The VA's standard treatments fail 40% of patients. Here's what the clinical evidence shows about psilocybin — and why the VA hasn't adopted it yet.
Up to 30% of long COVID patients develop PTSD-like symptoms. The connection between COVID-19 and PTSD is biological, not just psychological. Here's what the research shows.
Shrooomz Recover is a two-bottle AM/PM botanical supplement system designed for post-viral recovery. Here's everything you need to know about how it works, what's in it, and what to expect.
Long COVID impairs neuroplasticity through inflammation, BDNF reduction, and synaptic damage. Psilocybin is one of the most potent neuroplasticity promoters known. Here's what the intersection looks like.
Anxiety affects 40% of long COVID patients. Special mushroom supplements — particularly lion's mane, reishi, and psilocybin — address the neurobiological mechanisms driving post-COVID anxiety.
Depression affects 30–40% of long COVID patients. It's not just a reaction to being ill — it has specific neurobiological causes. Here's what the research shows about why it happens and what actually helps.
Lion's mane and cordyceps address two of the core mechanisms in post-viral syndromes: neurological damage and mitochondrial dysfunction. Here's what the clinical evidence shows.
Long COVID brain fog affects an estimated 1.9 million Americans. Emerging research on psilocybin's neuroplasticity effects suggests a potential mechanism for recovery. Here's what the evidence shows.
Long COVID fatigue affects 58% of long COVID patients at 12 months. Here's what the clinical evidence shows for supplements, ranked by strength of evidence.
Autoimmune conditions involve an immune system that attacks the body's own tissue. Certain functional mushrooms — particularly reishi and turkey tail — have shown immunomodulatory effects in clinical research.
Burnout isn't just tiredness. It's a state of neurological depletion where the brain's reward system stops responding. Psilocybin research is showing why it may help when rest alone doesn't.
Anorexia nervosa has the highest mortality rate of any psychiatric condition. Psilocybin's ability to disrupt rigid thought patterns makes it a compelling candidate. Here's the evidence.
Lion's mane mushroom stimulates nerve growth factor (NGF) production. Here's what that means, what the clinical evidence shows, and who it's most likely to help.
Depression paralysis isn't laziness. It's a neurological state where the brain's reward and motor systems shut down. Here's what the science says — and what actually shifts it.
Silicon Valley executives, artists, and writers have credited microdosing with enhancing creativity. Here's what controlled research actually shows — and what it doesn't.
Cordyceps became famous when Chinese athletes credited it for record-breaking performances in 1993. Here's what the actual research shows about VO2max, ATP production, and endurance.
Grief is not a disorder — but complicated grief is. When normal grief becomes stuck, it looks like depression but responds differently to treatment. Here's what psilocybin research shows.
The most consistent and dramatic results in psilocybin research come from studies of people facing terminal illness. Here's what the trials found and why the effects are so profound.
Social anxiety disorder affects 12% of adults. Standard treatments work for about half. Here's what psilocybin research shows for the other half.
In 2021, Imperial College London ran the first head-to-head trial of psilocybin against an SSRI. Here's what they found — and what it means for people who've tried antidepressants.
Psilocybin doesn't just change how you feel — it changes the physical structure of the brain. Here's what the neuroimaging research shows about synaptic growth and network rewiring.
Microdosing psilocybin has moved from underground practice to clinical research subject. Here's what the evidence says about protocols, dosing, and what to expect.
30-40% of people with depression don't respond to antidepressants. Here's what treatment-resistant depression actually is, why it happens, and what the evidence says works.
Heart palpitations, racing heart, and chest pain are among the most distressing long COVID symptoms. Here's the mechanism and what the research shows helps.
PTSD nightmares are not random bad dreams. They're the brain's failed attempt to process trauma during REM sleep. Here's the neuroscience and what actually works.
Functional mushrooms offer athletes a legal, evidence-based edge across three domains: energy production, recovery, and stress adaptation. Here's what the research shows.
Reishi has been used for sleep in traditional medicine for 2,000 years. Here's what modern clinical research shows about its mechanisms and effectiveness.
Women experience depression at twice the rate of men. Hormonal transitions — perimenopause, postpartum, PMS — drive much of this disparity. Here's what functional mushrooms offer.
Cognitive decline is not inevitable. Specific functional mushrooms have the strongest evidence base for neuroprotection in older adults. Here's what the research shows.
Complicated grief affects millions of people and responds poorly to standard treatments. Here's what the emerging research shows about psilocybin's potential for grief processing.
Microdosing psilocybin for anxiety is gaining traction as a research-backed alternative to benzodiazepines and SSRIs. Here's exactly how to do it.
Looking for the best psilocybin supplement for PTSD in 2026? This guide covers what the research supports, quality criteria, and how to use psilocybin safely for trauma.
The legal status of psilocybin is changing rapidly. Here's a comprehensive state-by-state guide to where psilocybin is legal, decriminalized, or still prohibited in 2026.
Understanding psilocybin dosing is essential for safe, effective use. This guide explains the difference between microdose, low dose, and high dose — and what each is used for.
Psilocybin has shown remarkable results in clinical trials for alcohol, tobacco, and opioid addiction. Here's what the research shows and what it means.
Bipolar depression is harder to treat than unipolar depression. Here's what the emerging research shows about psilocybin's potential — and the important safety considerations.
Looking to buy psilocybin gummies online? This guide covers what to look for, how to verify quality, and where to find reputable sources in 2026.
Burnout affects millions of professionals and responds poorly to standard interventions. Here's what the emerging research shows about psilocybin's potential for recovery.
Many people with ADHD are turning to psilocybin microdosing as an alternative to stimulants. Here's what the emerging research and user reports show.
Morning anxiety — the dread that hits before you get out of bed — responds well to psilocybin microdosing. Here's the neuroscience and the protocol.